BANK VONTOBEL/CALL/NOVO NORDISK ADR B/145/0.1/20.12.24 Stock BANK VONTOBEL/CALL/NOVO NORDISK ADR B/145/0.1/20.12.24
Add to a list
To use this feature you must be a member
Log inSign up

BANK VONTOBEL/CALL/NOVO NORDISK ADR B/145/0.1/20.12.24 Share Price

Warrant

DE000VD0HDA8

Delayed Deutsche Boerse AG 05:32:09 27/06/2024 pm IST
1.31 EUR -0.76% Intraday chart for BANK VONTOBEL/CALL/NOVO NORDISK ADR B/145/0.1/20.12.24
Current month+55.29%
1 month+34.69%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart NOVO NORDISK A/S
Chart BANK VONTOBEL/CALL/NOVO NORDISK ADR B/145/0.1/20.12.24

Latest news about NOVO NORDISK A/S

Thinking about trading options or stock in Tesla, Microsoft, Novo Nordisk, Intel, or Solaredge Technologies? PR
Thinking about buying stock in NKGen Biotech, Novo Nordisk, SoundHound AI, Safety Shot, or Energy Fuels? PR
Thinking about buying stock in Estrella Immunopharma, Novo Nordisk, C4 Therapeutics, Plug Power, or LQR House? PR
Thinking about buying stock in Transphorm Technology, Stronghold Digital Mining, Broadcom, Novo Nordisk, or Datadog? PR
More news

Quotes 5-day view

Date Price Change
27/24/27 1.31 -0.76%
26/24/26 1.32 -10.20%
25/24/25 1.47 +22.50%
24/24/24 1.2 -0.83%
21/24/21 1.21 -0.82%

Delayed Quote Deutsche Boerse AG

Last update June 27, 2024 at 05:32 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
IssuerLogo Issuer Vontobel Vontobel
WKN VD0HDA
ISINDE000VD0HDA8
Date issued 16/02/2024
Strike 145 $
Maturity 20/12/2024 (176 Days)
Parity 10 : 1
Emission price 0.67 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.53 €
Lowest since issue 0.58 €
Delta0.56x
Omega 5.758
Premium10.74x
Gearing10.19x
Moneyness 0.9908
Difference Strike 1.33 $
Difference Strike %+0.92%
Spread 0.01 €
Spread %0.76%
Intrinsic value 0.000000

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007 DKK
Average target price
937.9 DKK
Spread / Average Target
-6.86%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant